

25. The nucleic acid of claim 1, wherein the nucleic acid comprises a polynucleotide sequence selected from GACGCCGGAGG (SEQ ID NO: 38) and GACGTCGGAG (SEQ ID NO: 39).

29. The nucleic acid of claim 1, wherein the nucleic acid comprises the polynucleotide sequence AATGGGCGGTC (SEQ ID NO: 40).

73. The composition of claims 70 or 71, wherein the composition is administered to the subject by a route selected from the group consisting of intradermal, subdermal, subcutaneous, intramuscular, intravenous, intraperitoneal, and intrathecal.

REMARKS


Claims 1-103 are pending in this application. The above amendments merely add the Sequence Listing and sequence identifier numbers to the claims and correct a typographical error, and therefore introduce no new matter.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF
JONATHAN ALAN QUINE
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Respectfully submitted,


Emily M. Haliday, J.D., Ph.D.
Reg. No. 38,903

MARKED COPY OF AMENDED CLAIMS IN USSN 09/886,942

25. The nucleic acid of claim 1, wherein the nucleic acid comprises a polynucleotide sequence selected from GACGCCGAGG (SEQ ID NO: 38) and GACGTCGGAG (SEQ ID NO: 39).

29. The nucleic acid of claim 1, wherein the nucleic acid comprises the polynucleotide sequence AATGGGCGGTC (SEQ ID NO: 40).

73. The composition of [claim 75] claims 70 or 71, wherein the composition is administered to the subject by a route selected from the group consisting of intradermal, subdermal, subcutaneous, intramuscular, intravenous, intraperitoneal, and intrathecal.